Nuevos fármacosf. Pere Domingo Malalties Infeccioses Hospital de la Santa Creu i Sant Pau Barcelona
|
|
- Alexander Hodge
- 6 years ago
- Views:
Transcription
1 Nuevos fármacosf Pere Domingo Malalties Infeccioses Hospital de la Santa Creu i Sant Pau Barcelona pdomingo@santpau.cat
2 Fármaco Compañí ñía Familia Nº abstract GS-7340 Gilead ITIAN 152LB GSK GSK ITINAN 520, 628, 631 Cenicriviroc Takeda Pharm CCR5 54LB VIRIP MHH Inh. entrada 58LB Ibalizumab ADCAR AcAnti-CD4 585 BMS BMS Inh. unión 487 BMS BMS Inh. unión 518 BMS BMS Inh. unión 588
3 Fármaco Compañí ñía Familia Nº abstract GS-7340 Gilead ITIAN 152LB GSK GSK ITINAN 520, 628, 631 Cenicriviroc Takeda Pharm CCR5 54LB VIRIP MHH Inh. entrada 58LB Ibalizumab ADCAR AcAnti-CD4 585 BMS BMS Inh. unión 487 BMS BMS Inh. unión 518 BMS BMS Inh. unión 588
4 GS-7340
5 GS-7340 Demonstrates Greater Declines in HIV-1 RNA than Tenofovir Disoproxil Fumarate During 14 Days of Monotherapy in HIV-1 Infected Subjects M Markowitz, 1 A Zolopa, 2 * P Ruane, 3 K Squires, 4 L Zhong, 5 BP Kearney, 5 and W Lee 5 1 Aaron Diamond AIDS Research Center, New York, NY; 2 Stanford University Positive Care Clinic, Palo Alto, CA; 3 Lighthouse Medical, Los Angeles, CA; 4 Thomas Jefferson University, Philadelphia, PA; 5 Gilead Sciences, Foster City, CA 18 th Conference on Retroviruses and Opportunistic Infections March 2, 2011 Paper # 152LB
6 Introduction GS-7340 is a novel amidate prodrug that was designed to deliver high concentrations of tenofovir diphosphate to lymphoid cells The targeted delivery to lymphatic tissue should allow for a low dose and minimal systemic levels of tenofovir Chronic safety studies in dogs and rats demonstrate a greater therapeutic index relative to TDF M Markowitz, et al., CROI 2011; Paper # 152LB.
7 GS-7340: Targeting Lymphoid Cells O P HO OH O N N NH 2 N N O O O O O P O O O O O Tenofovir TDF GS-7340 N N NH 2 N N O O O P N H O O N N NH 2 N N EC 50 HIV-1 (PBMCs) 1.2 µm µm µm GS-7340 is 400-fold more potent than tenofovir in PBMCs 1 GS-7340 is 200-fold more stable in plasma than TDF resulting in circulating levels of prodrug 1 GS-7340 is rapidly metabolized inside the lysosomes of lymphoid cells by the enzyme cathepsin A 2 M Markowitz, et al., CROI 2011; Paper # 152LB. 1 Lee et al. Antimicrob Agents Chemother Birkus et al. Antimicrob Agents Chemother 2007
8 Increased Distribution to PBMCs In Vivo Plasma to PBMC ratio following administration of TFV, TDF or GS-7340 to dogs (10 mg-eqv/kg) 1 1:140 c 1:1.4 1:5 Subcut. Oral M Markowitz, et al., CROI 2011; Paper # 152LB. 1 Lee et al. Antimicrob Agents Chemother 2005
9 Objectives Primary Objectives To evaluate the antiviral potency of 2 different doses of GS-7340 as compared to TDF Primary endpoint: DAVG at Week 2 To determine the safety of GS-7340 over 14 days Secondary Objectives To determine the plasma and intracellular PK of GS-7340 To determine the viral dynamics of HIV-1 RNA in plasma M Markowitz, et al., CROI 2011; Paper # 152LB.
10 Study Design HIV-1-infected adults ART Treatment-naïve HIV-1 RNA 15,000 c/ml CD4 count 200 cells/mm 3 Randomized, double-blind 3 arm study TDF 300 mg (active control arm) GS mg GS mg Monotherapy for 14-day once-daily dosing M Markowitz, et al., CROI 2011; Paper # 152LB.
11 Baseline Characteristics TDF 300mg (N=10) GS mg (N=10) GS mg (N=10) Age (mean) 34.8 ± ± ± 6.5 Sex (males) Ethnicity Caucasian Black Latino Asian Mean HIV-1 RNA (log 10 copies/ml) 5.03 ± ± ± 0.30 Mean CD4 cell count 384 ± ± ± 108 M Markowitz, et al., CROI 2011; Paper # 152LB.
12 Primary Efficacy Endpoint Treatment (10 pts/arm) TDF 300 mg GS mg GS mg Mean DAVG 2 [log 10 c/ml] ± ± ± 0.14 p-value vs. TDF 300 mg M Markowitz, et al., CROI 2011; Paper # 152LB.
13 Viral Dynamics Treatment (10 pts/arm) Mean VL Day 14 [log 10 c/ml] p-value of mean VL vs. TDF 300 mg Mean first phase decay slope p-value of mean decay slope vs. TDF 300 mg TDF 300 mg ± ± GS mg ± ± GS mg ± ± M Markowitz, et al., CROI 2011; Paper # 152LB.
14 Viral Dynamics Viral Load from Baseline (log 10 c/ml) TDF 300 mg GS mg GS mg Day M Markowitz, et al., CROI 2011; Paper # 152LB.
15 Tenofovir Levels in Plasma: PK Profile on Day Tenofovir in plasma [ng/ml] AUC 0-24h 56%* 88%* TDF 300 mg GS mg GS mg * p-value <0.001 Hours M Markowitz, et al., CROI 2011; Paper # 152LB.
16 Tenofovir Diphosphate in PBMCs 10 33x Tenofovir-DP in PBMCs [um] 1 8x 18x* 4x * TDF 300 mg GS mg GS mg 0.1 Day 3 Day 14 * p-value <0.05 M Markowitz, et al., CROI 2011; Paper # 152LB.
17 Safety and Resistance No dose interruptions or discontinuations No serious adverse events No clinically significant laboratory abnormalities Most frequent adverse events were mild to moderate headache and nausea No resistance mutations to GS-7340 or TDF were detected at day 14 in any subject M Markowitz, et al., CROI 2011; Paper # 152LB.
18 Summary Monotherapy with GS-7340 at 50 or 150 mg led to significantly greater decreases in HIV-1 RNA and at lower systemic tenofovir exposures than with TDF 300 mg GS-7340 is a next generation oral prodrug of tenofovir that has the potential to improve upon the efficacy and safety of TDF for the treatment of HIV The lower dose of GS-7340 will permit the development of new single tablet regimens that are not possible today GS-7340 has the potential of making tenofovir more widely available in resource limited settings given the relative manufacturing expense compared to TDF M Markowitz, et al., CROI 2011; Paper # 152LB.
19 BMS Inhibidores del acoplamiento
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 Infusión n de CD4 autólogos R5/X4- defectivos
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53 Creating HIV-resistant CD4+ T cells with CXCR4- zinc finger nucleases Craig Wilen Lab of Robert Doms University of Pennsylvania
54 Long term-goal: recapitulate the Berlin patient by genome editing the HIV coreceptor genes Adoptive therapy phase I trial with CCR5-ZFNs is currently underway. ~50% of ART-experienced individuals have R5X4 or X4 HIV. CXCR4-ZFNs may protect against X4 HIV and can be combined with CCR5-ZFNs treatment to create completely HIV-resistant CD4+ T cells. By disrupting CXCR4 in CD4+ T cells we avoid toxicities associated with systemic disruption.
55 X4-ZFNs specifically bind, cleave, and disrupt the cxcr4 gene
56 CXCR4-ZFNs efficiently disrupt cxcr4 in CD4+ T cells and do not adversely affect cell growth Ad5/F35 X4-ZFN Ad5/F35 GFP
57 The most common CXCR4 mutation is an in-frame deletion that does not traffic to the cell surface 80% of mutations are deletions. In-frame deletions occur 2.5 fold more frequently than predicted. An 18bp deletion, CXCR4 18, is the most common mutation and does not traffic to the cell surface. Sean Patro
58 X4-ZFN treatment of CD4+ T cells preserves cell growth and viability in the presence of HIV Mock HIV Bk132: Primary X4 HIV Cumulative live cell count HxB: Lab adapted X4 HIV R3A: Primary dual tropic HIV NTD R5ZFN X4ZFN Time (days)
59 Survival advantage in the presence of HIV is due to CXCR4 disruption 19 days post infection
60 CXCR4 disruption confers protection from X4 HIV in humanized mice X4-ZFNs conferred protection by 14 dpi, but this effect waned over time. Evolution or outgrowth of preexisting R5X4 HIV observed in X4- ZFN but not R5-ZFN-treated mice.
61 Conclusions CXCR4-ZFNs specifically and efficiently disrupt CXCR4. X4-ZFNs confer robust protection of CD4+ T cells from X4 HIV challenge in vitro. CXCR4 disruption confers protection from X4 HIV in humanized mice, resulting in outgrowth of R5X4 HIV. Future studies aim to combine CCR5- and CXCR4-ZFNs to eliminate HIV coreceptor expression.
62 La crisis se produce cuando lo viejo no acaba de morir y cuando lo nuevo no acaba de nacer Bertolt Brecht ( ) 1956)
Dolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationCROI 2015: Treatment and Cure Highlights
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2015: Treatment and Cure Highlights Shireesha Dhanireddy Robert Harrington March 17, 2014 No financial conflicts of interest Outline Treatment Studies
More informationEvidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation
Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.
More informationClinical considerations in switching antiretroviral therapy
Clinical considerations in switching antiretroviral therapy David Jilich Department of Infctious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital 4th CEE Meeting
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationMedian (Min Max) CVC 100 mg + EFV placebo + TDF/FTC (N=8) CVC 200 mg + EFV placebo + TDF/FTC (N=10) LLOQ=5.00 ng/ml Time (h)
600 Pharmacokinetics (Pk) of cenicriviroc (cvc) following 100 or 200 mg once-daily Dosing with open-label tenofovir / emtricitabine (tdf/ftc) in hiv-1 infected subjects enrolled in a Phase 2b study David
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2006-2011 2012+ 3 rd Gen. HAART 3 rd Generation Future HAART: 2012 + THE FUTURE OF ANTIRETROVIRAL THERAPY New drugs INSTI: Elvitegravir,
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationSingle and Multiple Dose Pharmacokinetics and Safety in Non-HIV-Infected Healthy Subjects Dosed with BMS , an Oral HIV Attachment Inhibitor
Single and Multiple Dose Pharmacokinetics and Safety in on-hiv-infected Healthy Subjects Dosed with 66368, an Oral HIV Attachment Inhibitor Richard ettles, Caly Chien, Erica Elefant, Xiaodong Wang, Ellen
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationRoy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDidactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15
Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationHIV life cycle revisited: What s new in basic science? Theresa Rossouw
HIV life cycle revisited: What s new in basic science? Theresa Rossouw Outline of the Presentation Lifecycle overview New drugs & therapies Cell entry Co-receptor binding Attachment Keeping it Simple
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationDevelopment of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
More informationAntiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies
Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies Craig W. Hendrix, MD Director, Drug Development Unit Division of Clinical Pharmacology Johns Hopkins University
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationClinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Clinical Case Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Paris, January 16th 2018 Links of interest and Disclaimer Adviser, speaker, investigator for: Abbvie, BMS,
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationInvestigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents
Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents Joseph J. Eron MD Professor of Medicine University of North Carolina Chapel Hill, North Carolina Learning Objectives
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationTAF an overview Who? When? How? co-infected/ monoinfected
TAF an overview Who? When? How? co-infected/ monoinfected Dr Kosh Agarwal Institute of Liver Studies King s College Hospital ICVH Chicago 2017 Disclosures I am a Hepatologist Involved in the global TAF
More informationPharmacology Lessons from Chemoprophylaxis Studies. Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK
Pharmacology Lessons from Chemoprophylaxis Studies Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK Pre tenofovir generation 1996-2009 PK did not inform trials
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationPresentation #: OP221
Pharmacokinetics, Safety and Tolerability of, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects Presentation #: OP22 Tawesak Tanwandee,
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationTenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study Robert T.Schooley, Peter Ruane a, Robert A.Myers b, Gildon Beall c, Harry Lampiris d, Daniel
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationDrug Penetration to Sanctuary Sites Oral vs. IV Administration
Drug Penetration to Sanctuary Sites Oral vs. IV Administration Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases University
More informationHIV IS NOT OVER. Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Learning Objectives
Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Davey M. Smith, MD, MAS Professor of Medicine University of California San Diego San Diego, California Learning Objectives
More informationEXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE
EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCROI 2016: Top Ten for Clinicians
Hynes Convention Center. Boston, MA; US. Feb 22-25, 2016 CROI 2016: Top Ten for Clinicians Josep M Llibre Hospital Universitari Germans Trias i Pujol Fundació Lluita contra la SIDA Badalona, Barcelona
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationBASIC AND TRANSLATIONAL SCIENCE
BASIC AND TRANSLATIONAL SCIENCE Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationPhase 1 Human Trials of Rectal Microbicides
Phase 1 Human Trials of Rectal Microbicides UC781: Completed Tenofovir: Planned to start an NIH IPCP for Topical Microbicides RM Trials under U19-IPCP grant UC781 (topical) rectal trial completed A Phase
More informationThe HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationPharmacology Considerations for HIV Prevention
Pharmacology Considerations for HIV Prevention Peter L. Anderson University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Perspectives for next generation studies
More informationtenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd
tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationMTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir
MTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir Craig Hendrix, Alexandra Minnis, Vijayanand Guddera, Sharon Riddler, Robert Salata, Clemensia Nakabiito,
More informationInfertility Treatment and HIV
Infertility Treatment and HIV Infertility Treatment by IVF Or Intra-cytoplasmic Sperm Injections (ICSC) In Chronic HIV-1 Sero- discordant Couples (Poster 670) Retrospective study of outcome of IVF or ICSC
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationFuture Perspectives for Delivery of Antiretroviral Drugs
Future Perspectives for Delivery of Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationPharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin S Ramanathan, H Wang, T Stondell, A Cheng, and BP Kearney Gilead Sciences, Inc.,
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationHuman hematopoietic stem/progenitor cells modified by zinc finger nucleases targeted
Supporting Online Material for: Human hematopoietic stem/progenitor cells modified by zinc finger nucleases targeted to CCR5 control HIV-1 in vivo Nathalia Holt 1, Jianbin Wang 2, Kenneth Kim 2, Geoffrey
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationInclusion/Exclusion Criteria
The Immunomodulatory Effects of Intensification among ART-suppressed Patients with Incomplete CD4 Recovery Peter W. Hunt, Nancy Shulman, Tim Hayes, Viktor Dahl, Ma Somsouk, Nick Funderburg, Alan L. Landay,
More informationNew Approaches to Hepatitis B Therapy
ew Approaches to Hepatitis B Therapy YSGE Course 2016 Ira M. Jacobson, M.D. Chairman, Department of Medicine Mount Sinai Beth Israel Professor of Medicine Icahn School of Medicine at Mount Sinai Themes
More informationInarigivir: A novel RIG-I agonist for chronic hepatitis B
: A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationSangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies
December 11, 2015 Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies Preliminary Data Suggest Adenoviral Delivery Method Superior for Immune Stimulation and Control of Viral
More informationThe Role of TAF in PrEP. Dr. Garrett has nothing to disclose
The Role of TAF in PrEP KATY GARRETT, PHARMD UNIVERSITY OF NORTH CAROLINA Dr. Garrett has nothing to disclose Outline PrEP Efficacy Adherence among populations Pharmacokinetic and pharmacodynamics relationship
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More information